| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T105 |
0-249 |
Sentence |
denotes |
Fig. 4 Ability of SARS-CoV-2 RBD to inhibit viral entry, as well as its cross-reactivity and cross-neutralizing activity with SARS-CoV. a Dose-dependent inhibition of SARS-CoV-2 RBD protein against pseudotyped SARS-CoV-2 entry into hACE2/293T cells. |
| T106 |
250-333 |
Sentence |
denotes |
SARS-CoV and MERS-CoV RBDs, as well as hDPP4/293T cells, were included as controls. |
| T107 |
334-548 |
Sentence |
denotes |
SARS-CoV-2 RBD protein inhibited entry of SARS-CoV-2 and SARS-CoV pseudoviruses into their respective target (hACE2/293T) cells (a), but not the entry of MERS-CoV pseudovirus into its target (hDPP4/293T) cells (a). |
| T108 |
549-667 |
Sentence |
denotes |
SARS-CoV RBD protein inhibited both SARS-CoV-2 and SARS-CoV pseudovirus entry, but not MERS-CoV pseudovirus entry (b). |
| T109 |
668-792 |
Sentence |
denotes |
MERS-CoV RBD inhibited neither SARS-CoV-2 nor SARS-CoV pseudovirus entry, but it did inhibit MERS-CoV pseudovirus entry (c). |
| T110 |
793-1202 |
Sentence |
denotes |
The data are presented as mean inhibition (%) ± s.e.m. (n = 4), and 50% inhibition concentration (IC50) was calculated for SARS-CoV-2 RBD (a, b, black), or SARS-CoV RBD (a, b, red), protein against SARS-CoV-2 pseudovirus and SARS-CoV pseudovirus and for MERS-CoV RBD protein (green) against MERS-CoV pseudovirus (c). d Cross-reactivity of SARS-CoV-2 RBD protein with SARS-CoV RBD-specific mouse sera by ELISA. |
| T111 |
1203-1291 |
Sentence |
denotes |
Sera of mice immunized with mammalian cell-expressed SARS-CoV RBD protein30 were tested. |
| T112 |
1292-1389 |
Sentence |
denotes |
Sera of mice immunized with mammalian cell-expressed MERS-CoV RBD protein31 were used as control. |
| T113 |
1390-1443 |
Sentence |
denotes |
The data are presented as mean A450 ± s.e.m. (n = 4). |
| T114 |
1444-1831 |
Sentence |
denotes |
The IgG antibody (Ab) titers were calculated as the endpoint dilution that remains positively detectable for SARS-CoV-2 RBD (black), or SARS-CoV RBD (red), binding to anti-SARS-CoV RBD sera (d) and for MERS-CoV RBD (green) binding to anti-MERS-CoV RBD sera (e). f Cross-neutralization of SARS-CoV RBD-immunized mouse sera against SARS-CoV-2 infection by pseudovirus neutralization assay. |
| T115 |
1832-1887 |
Sentence |
denotes |
MERS-CoV RBD-immunized mouse sera were used as control. |
| T116 |
1888-1955 |
Sentence |
denotes |
The data are presented as mean neutralization (%) ± s.e.m. (n = 4). |
| T117 |
1956-2207 |
Sentence |
denotes |
50% neutralizing antibody titers (NT50) were calculated against SARS-CoV-2 pseudovirus (black), or SARS-CoV pseudovirus (red), (f) infection in hACE2/293T target cells, as well as against MERS-CoV pseudovirus (green) (g) infection in hDPP4/293T cells. |
| T118 |
2208-2267 |
Sentence |
denotes |
Experiments were repeated twice and yielded similar results |
